TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Support in Patients With Nutritional Risk. How we Can Improved the Prognosis and Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* MUST =\>2~* Region of living Bney-Brak or Petah-tikwa~* Fine cognitive state~Exclusion Criteria:~* Progressive cancer~* Dementia~* Fiddling by PEG or Enteral nutrient via Naso gastric tube~* Psychiatrics disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Measurements and questioners
- Group A (Type: ACTIVE_COMPARATOR): Receiving Food dish every night for 6 months Measurements and questioners
- Group B (Type: ACTIVE_COMPARATOR): Receiving Food dish every night for 6 months, at this group extra attention have given to the dish plating and appearance by professional (BOCUSE), Measurements and questioners

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with disease at least 3 months before study~* Muscle weakness~* Received corticosteroids with or with out disease modifying antirheumatic drugs at least 3 months before study however not responding to this therapy~Exclusion Criteria:~* Other idiopathic inflammatory myopathies~* Myopathy other than polymyositis and dermatomyositis~* Patients with late stages of disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- BAF312 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Discovering FFC-MRI Biomarkers of Alzheimer Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with probable Alzheimer's disease, based upon cognitive testing (MMSE) and SPECT imaging.~* Controls will be participants without known cognitive impairment or Alzheimer's disease.~* Subjects capable of giving informed consent.~* Age 21 and above~Exclusion Criteria:~* MRI-incompatible condition detected in the MR screening sheet such as some metallic implanted devices (see MR screening sheet in the project files).~* Claustrophobia~* Waist circumference larger than 102 cm, due to the limited bore size of the scanner.~* Restrictions to mobility such that patients are unable to be positioned in scanner by trained research radiographer e.g. severe kyphosis~* Cognitive impairment of sufficient severity that the participant does not have capacity to give informed consent~* Pregnancy~* Persons who might not adequately understand verbal explanations or written information given in English, or who have special communication needs~* Dementia of sufficient severity that the participant cannot give informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 120 Years
- Healthy Volunteers: t

Study Arms:
- Alzheimer's patients (Type: EXPERIMENTAL): Patient diagnosed with early onset Alzheimer's disease.
- Control (Type: ACTIVE_COMPARATOR): Healthy volunteers that do not have Alzheimer's disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs~* Participants must have had at least one endocrine therapy~* Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study~* If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study~Exclusion Criteria:~* Participants must not have breast cancer that has spread to the brain if untreated and with symptoms~* Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy~* Participants must not have certain active infections including HIV or hepatitis~* Participants must not be pregnant or breastfeeding~* Participants must not have certain types of cancers or certain previous cancer treatments~* Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib + Fulvestrant (Type: EXPERIMENTAL): 150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
- Standard Chemotherapy (Type: ACTIVE_COMPARATOR): Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female ≥ 18 yrs~* Baseline HCV RNA \> 1000 IU/ml~* Cirrhosis with current or prior decompensation~* HCV (Hepatitis C Infection) Genotype 3~* Treatment naïve or treatment experienced~Exclusion Criteria:~* HIV or HBV (Hepatitis B Virus) co-infection~* Recent Variceal bleed~* Pregnancy~* Haemolytic anaemia~* Platelet counts \<20,000/ml~* Advanced HCC (Hepatocellular Carcinoma)~* Renal dysfunction, GFR (glomerular filtration rate) \< 30 ml/min~* Haemoglobin \< 10 g/dl~* MELD (Model for End Stage Liver Disease) \>25, CTP (Child-Turcotte-Pugh score) \>12~* Post organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir + Ribavirin 1 (Type: ACTIVE_COMPARATOR): Sofosbuvir + Ribavirin x 24 weeks
- Sofosbuvir + Ribavirin 2 (Type: EXPERIMENTAL): Sofosbuvir + Ribavirin x 36 weeks
- Sofosbuvir + Ribavirin 3 (Type: EXPERIMENTAL): Sofosbuvir + Ribavirin x 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years old or older~  * Able to provide consent for participation~ * Fluency in English~ * Presenting for first-time Mohs surgery for treatment of a cutaneous malignancy~Exclusion Criteria:~* • Patients under 18 years old~  * Prisoners~ * Patients unable to provide consent~ * History of prior Mohs surgery~ * Patients requiring multi-disciplinary care (i.e. Involvement of other surgical specialties such as Plastic Surgery or Ophthalmology for reconstruction)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Pre-operative Consultation (Type: None): None
- No consultation (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Arm Motor Control on Bi and Uni ADLs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Study will include subjects 18 years of age or older from any of the below groups:~* Stroke survivors, 3 months post event~* Upper extremity amputees, 3 months post event~* Cervical SCI (C-5 to C-7), 3 months post event~* Cerebral palsy participants~* Healthy participants~Exclusion Criteria:~* The inability to perform at least some aspects of ADL tasks such as drinking, pouring, pinching, and grasping.~* Severe spasticity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Upper Limb Assessment on ADLs (Type: OTHER): Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with high risk recurrent or refractory solid tumors following initial chemotherapy~2. Tumor must be sensitive to chemotherapy (maximum 8 cycles) and/or radiation defined as a greater than 50% reduction in size of the primary and/or metastatic sites.~3. Patients who are under 35 years of age.~4. Patients with a life expectancy of at least 8 weeks and performance status (Karnofsky or Lansky score) of at least 70%.~5. Patients who are acceptable candidates for peripheral blood stem cell transplantation based on their pre-transplant evaluation.~Exclusion Criteria:~1. Patients will not be excluded based on sex, race.~2. Patients with central nervous system tumors are not eligible for this protocol.~3. Patients have significant functional deficits in major organs which would interfere with successful outcome following PBSCT.~4. Patients who have been treated for infections must have appropriate responses as documented by negative cultures and/or a normal radiographic examination.~5. Patients may not have active CNS disease or marrow involvement with the tumor at the time of transplant.~6. Patients with disease progression after tandem PBSC #1 will not be eligible for tandem PBSC #2.~7. Patients will be excluded if they are women of childbearing potential who are currently pregnant (HCG+) or who are not practicing adequate contraception.~8. Patients who have had a previous stem cell transplant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who provide written informed consent.~* Subjects who have an ileostomy and be over 18 years of age.~* Subjects who are currently using a one piece drainable pouch.~* Subjects who have unbroken peri-stomal skin (healthy normal skin defined as normal unbroken skin with certain variations normal for this subject to L1 on the SACs Instrument Scale).~* Subjects with a stoma considered 'normal' in appearance in accordance with the stoma, colour, moisture and structure rating scales.~* Subjects who are willing to attend clinic for a maximum of 5 separate occasions for scheduled visits.~* Subjects who are willing to discontinue the use of pastes, adhesive strips and rings/seals used to seal the area between the skin barrier wafer and stoma during the use of the study device.~* Subjects who other than their ileostomy considered to have a healthy/stable health status.~* Subjects who have good manual dexterity and be able to take care of their stoma independently, or have a consistent care provider.~* Subjects who are willing and able to complete a diary card for the duration of the study.~Exclusion Criteria:~* Subjects with a history of sensitivity to any one of the ostomy products or the components being studied.~* Subjects with stoma duration of less than 3 months.~* Subjects who currently use a belt with their usual appliance.~* Subjects who have been entered into the study before, or who have previously taken part in a study in the last month.~* Subjects who require convexity or other skin fillers (pastes, rings, seals) to even undulations of the skin.~* Subjects undergoing chemotherapy or radiotherapy.~* Subjects who have any other medical condition which, according to the investigator justifies exclusion from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Type A Pouch followed by Type B pouch (Type: EXPERIMENTAL): Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
- Type B Pouch followed by Type A pouch (Type: EXPERIMENTAL): Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Assisted Hatching on Vitrified Embryo Transfer Clinical Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women age 18-42,~* cleavage-stage embryo transfer,~* less than seven IVF cycles with fresh embryo transfer,~* high quality embryos.~Exclusion Criteria:~* out of 18-42 y.o.~* blastocyst embryo transfer~* more or equal to seven IVF cycles with fresh embryo transfer~* low quality embryos

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- No Assisted Hatching (Type: NO_INTERVENTION): No Assisted Hatching
- Assisted Hatching (Type: ACTIVE_COMPARATOR): Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be a Kansas City Veterans Hospital patient who is enrolled in the MOVE weight loss program~* Patients with a BMI \> 25 with associated co-morbid medical conditions such as diabetes, high blood pressure, high cholesterol, arthritis, heart disease, low back pain, sleep apnea, or other obesity associated condition.~* Enrollment in MOVE program is optional for patients with a BMI \> 25 with no co-morbid medical conditions.~* Enrollment for patients 70 years or older with BMI \> 25 is optional and requires mandatory medical clearance prior to beginning new physical activity and closer nutritional supervision to minimize protein, vitamin and mineral deficiencies.~Exclusion Criteria:~* Active cancer other than non-melanoma skin cancer~* End stage COPD, congestive heart failure~* End stage neurologic disorder (Parkinson's, ALS, MS)~* Long-term care facility resident~* End stage renal disease~* Moderate to severe cognitive impairment (dementia, post-stroke)~* Active psychosis or substance abuse~* AIDS (except asymptomatic HIV infection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Obese individuals with weight loss (Type: EXPERIMENTAL): Self support, group sessions
- Obese individuals without weight loss (Type: EXPERIMENTAL): self support, group sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~i) Administrative - The subject is able to understand the study, is willing to give voluntary, written, informed consent, will co-operate with assessment procedures and is geographically able to comply with the post-operative follow-up regime.~ii) Age - The subject's age is between 18 and 75 years inclusive.~iii) Sex - Male or female subjects may be recruited to the study.~iv) Diagnosis -Subjects must be undergoing primary THR surgery for non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis, post-traumatic arthritis, fractured neck of femur and non-union of fractured neck of femur, SUFE or Perthes disease.~v) Suitability - Subjects who in the opinion of the Investigator are considered to be suitable for treatment with the devices involved in the study.~Exclusion Criteria:~i) Subjects undergoing revision procedure to the operative hip.~ii) Subjects who have had a previous femoral osteotomy to the operative hip.~iii) Subjects who have a history of active sepsis in the joint.~iv) Subjects who have been diagnosed with primary or secondary carcinomas in the last five years (excluding basal cell carcinoma or cervical carcinoma).~v) Subjects with any condition which may, in the opinion of the Investigator, interfere with the total hip replacement's survival or outcome, e.g. Paget's disease, Charcot's disease.~vi) Subjects with psycho-social disorders which, in the opinion of the Investigator would limit rehabilitation.~vii) Subject's whose weight is \> 100kg.~viii) Subjects with femoral head necrosis on the non-operated side (RSA and DEXA subjects only).~ix) Subjects who have a fracture of the femur \> 6 months old (RSA and DEXA subjects only).~x) Subjects diagnosed as having ankylosing spondylitis (RSA and DEXA subjects only)~xi) Subjects with a known history of poor compliance to medical treatment.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- European Hip (Type: OTHER): A cementless femoral component for use in total hip replacement
- Zweymüller (Type: ACTIVE_COMPARATOR): A cementless femoral component for use in total hip replacement
- CLS Spotorno (Type: ACTIVE_COMPARATOR): A cementless femoral component for use in total hip replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues